CLD-202
/ Calidi Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 23, 2023
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
(Businesswire)
- "Calidi Biotherapeutics...today announced the commitment of $25 million in Series B funding led by Jackson Investment Group ('JIG'), who has funded an initial investment of $5 million....The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications."
Financing • Oncology
1 to 1
Of
1
Go to page
1